Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of$ 0.70. This compares to loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 62.86%. A quarter ago, it was expected that this pharmaceutical company would post a loss of$ 1.85 per share when it actually produced a loss of $0.64, delivering a surprise of 65.41%.Over the last four quarters, the ...